Mary Kay Fenton

2022 - Tourmaline Bio

In 2022, Mary Kay Fenton earned a total compensation of $2.2M as Former Interim Chief Executive Officer and President and Chief Financial Officer at Tourmaline Bio.

Compensation breakdown

Non-Equity Incentive Plan$131,783
Option Awards$1,301,440
Salary$455,000
Stock Awards$308,800
Other$12,200
Total$2,209,223

Fenton received $1.3M in option awards, accounting for 59% of the total pay in 2022.

Fenton also received $131.8K in non-equity incentive plan, $455K in salary, $308.8K in stock awards and $12.2K in other compensation.

Rankings

In 2022, Mary Kay Fenton's compensation ranked 1,625th out of 5,753 executives tracked by ExecPay. In other words, Fenton earned more than 71.8% of executives.

ClassificationRankingPercentile
All
1,625
out of 5,753
72nd
Division
Manufacturing
837
out of 3,133
73rd
Major group
Chemicals And Allied Products
330
out of 1,419
77th
Industry group
Drugs
306
out of 1,320
77th
Industry
Biological Products, Except Diagnostic Substances
75
out of 291
74th
Source: SEC filing on April 19, 2024.

Fenton's colleagues

We found two more compensation records of executives who worked with Mary Kay Fenton at Tourmaline Bio in 2022.

2022

Scott Requadt

Tourmaline Bio

Chief Executive Officer

2022

Michael Zdanowski

Tourmaline Bio

Chief Technology Officer

News

In-depth

You may also like